Advertisement

Somatostatin pp 339-353 | Cite as

Clinical Applications of Somatostatin Analogs

  • Peter Marbach
  • Michael Neufeld
  • Janos Pless
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 188)

Abstract

It has often been shown that tetradecapeptide somatostatin (S-14), discovered in 1973 by Brazeau et al. (1), is effective in the treatment of acromegaly, as adjunct to insulin therapy of type I diabetes, in stopping gastrointestinal bleeding, in treatment of carcinoid syndrome, etc. But S-14 has always had to be given as an iv infusion, which has severely limited its practical application. It was therefore an important exercise of peptide chemists to improve the metabolic stability of the molecule, i.e. to synthesize analogs with a longer duration of action. However, until quite recently, little progress had been made in providing clinically useful compounds.

Keywords

Acromegalic Patient Carcinoid Syndrome Glucagon Release Increase Infusion Rate Octapeptide Analogue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brazeau P, Vale W, Burgus R, Ling N, Butcher IA, Rivier J, Guillemin R 1973 Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77.PubMedCrossRefGoogle Scholar
  2. 2.
    Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J 1982 SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133.PubMedCrossRefGoogle Scholar
  3. 3.
    Brazeau P, Vale W, Rivier J, Guillemin R 1974 Acylated Des[Ala1-Gly2]-somatostatin analogs: prolonged inhibition of growth hormone secretion. Biochem Biophys Res Commun 60: 1202.PubMedCrossRefGoogle Scholar
  4. 4.
    Evered DC, Gomez Pan A, Tunbridge WMG, Hall R, Lind T, Besser GM, Mortimer CH, Thorner MO, Schally AV, Kastin AJ, Coy DH 1975 Analogues of growth hormone release inhibiting hormone. Lancet 1: 1250.PubMedCrossRefGoogle Scholar
  5. 5.
    Raptis S, Zoupas CH, Mallas E, Moulopoulos S 1978 Effects of a new somatostatin analogue in insulin dependent diabetics. Diabetologia 15: 264.Google Scholar
  6. 6.
    Lenti G, Trovati M, Lorenzati R, Vitelli F, Tagliaferro V, Marocco A, Pagano GF 1980 Effect of a somatostatin analog on insulin requirement and hormone levels in 6 insulin-dependent juvenile-onset diabetics subjected to artificial pancreas. Acta Diabetologica Lat 17: 9.CrossRefGoogle Scholar
  7. 7.
    Trovati M, Massara F, Camanni F, Molinatti GM, Lorenzati R, Pagano GF 1980 Effect of the somatostatin analog D-Trpe, D-Cys14 on glucose, insulin, pancreatic glucagon and growth hormone plasma levels in acromegalics and mild diabetics. J Endocrinol Invest 3: 189.PubMedGoogle Scholar
  8. 8.
    Kahn R, Bhathena SJ, Recant L, Rivier J 1981 Use of somatostatin and somatostatin analogs in a patient with a glucagonoma. J Clin Endocrinol Metab 53: 543.PubMedCrossRefGoogle Scholar
  9. 9.
    Adrian TE, Barnes AJ, Long RG, O’Shaughnessy DJ, Brown MR, Rivier J, Vale W, Blackburn AM, Bloom SR 1981 The effect of somatostatin analogs on secretion of growth, pancreatic, and gastrointestinal hormones in man. J Clin Endocrinol Metab 53: 675.PubMedCrossRefGoogle Scholar
  10. 10.
    Long RG, Adrian TE, Brown MR, Rivier JE, Barnes AJ, Mallinson CN, Vale W, Christofides ND, Bloom SR 1979 Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue. Lancet 2: 764.PubMedCrossRefGoogle Scholar
  11. 11.
    Barnes AJ, Long RG, Adrian TE, Vale W, Brown MR, Rivier JE, Hanley J, Ghatei MA, Sarson DL, Bloom SSR 1981 Effect of a long-acting octapeptide analogue of somatostatin on growth hormone and pancreatic and gastrointestinal hormones in man. Clin Sci 61: 653.PubMedGoogle Scholar
  12. 12.
    Reding P, Naeije R, Melot C, Hallemans R, Mols P 1980 Action de deux types de somatostatine sur l’hémodynamique portale, pulmonaire et systémique du patient cirrhotique. Gastroentérologie Clin Biol (France) 4: 928.Google Scholar
  13. 13.
    Long RG, Peters JR, Grahame-Smith DC, O’Shaughnessy DJ, Vale W, Rivier JE, Brown MR, Bloom SR 1980 Effects of somatostatin on flushing and plasma gastrointestinal peptides in the carcinoid syndrome. Clin Sci 59: 9 P.Google Scholar
  14. 14.
    Long RG, Peters JR, Bloom SR, Brown IIR, Vale W, Rivier JE, Grahame-Smith DG 1981 Somatostatin, gastrointestinal peptides and the carcinoid syndrome. Gut 22: 549.PubMedCrossRefGoogle Scholar
  15. 15.
    Roti E, Ghinelli C, Baudini P, Del Rossi C, Emanuele R, Robuschi G, Gundi A 1981 Effects of somatostatin in a case of severe hypoglycemia due to nesidioblastosis. J Endocrinol Invest 4: 209.PubMedGoogle Scholar
  16. 16.
    Chernish STM, Miller RE, Rosenak BD, Brunelle RL 1981 Effect of D-Val1,D-Trp8 -somatostatin on the motility of the stomach, duodenum and jejunum. Am J Gastroenterol 75: 36.PubMedGoogle Scholar
  17. 17.
    Wajchenberg BL, Cesar FP, Leme CE, Borghi VC, Souza ITT, Neto DG, Germek OA, Coy DH, Comaru-Schally AM, Schally AV 1983 1983 Dissociated effects of somatostatin analogs on arginineinduced insulin, glucagon and growth hormone release in acromegalic patients. Horm Metab Res 15: 471.PubMedCrossRefGoogle Scholar
  18. 18.
    Dimitriadis G, Tessari P, Gerich J 1983 Effects of a longacting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus. Metabolism 32: 987.PubMedCrossRefGoogle Scholar
  19. 19.
    Veber DF, Freidinger RM, Perlow DS, Paleveda WJ, Holly FW, Strachan RG, Nutt RG, Arison BH, Homnick C, Randall WC, Glitzer MS, Saperstein R, Hirschmann R 1981 A potent cyclic hexapeptide analogue of somatostatin. Nature 292: 55.PubMedCrossRefGoogle Scholar
  20. 20.
    Skamene A, Patel YC 1984 Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones. Clin Endocrinol 20: 555.CrossRefGoogle Scholar
  21. 21.
    Spinas GA, Keller U, Varga L, Neufeld M 1984 Reduction of postprandial hyperglycemia and suppression of gastrointestinal hormones after s.c. administration of a new somatotatin analogue in type 1 diabetics. Eur J Clin Invest 14: 24.CrossRefGoogle Scholar
  22. 22.
    Plewe G, Beyer J, Krause U, Neufeld 14, del Pozo E, Program of the 7th International Congress of Endocrinology, Quebec City 1984 ( Abstract).Google Scholar
  23. 23.
    Friesen SR 1982 Tumours of the endocrine pancreas. New Engl J Med 306: 580.PubMedCrossRefGoogle Scholar
  24. 24.
    Wood SM, Polak JM, Bloom SR 1983 Gut hormone secreting tumours. Scand J Gastroenterol 18 (Suppl 82): 165.Google Scholar
  25. 25.
    Bonfils S, Rene E, Piginal F, Rambaud JC 1979 Rebound effect after somatostatin treatment in Verner Morrison syndrome. Lancet 2: 476.PubMedCrossRefGoogle Scholar
  26. 26.
    Sohier, J, Jeanmougin M, Lombrail P, Passa PH 1980 Rapid improvement of skin lesions in glucagonomas with intravenous somatostatin infusion. Lancet 1: 40.PubMedCrossRefGoogle Scholar
  27. 27.
    Dharmsathaphron K, Sherwin RS, Cataland S, Jaffe B, Dobbins J 1980 Somatostatin inhibits diarrhoea in the carcinoid syndrome. Am Int Med 92: 68.Google Scholar
  28. 28.
    Wood SM, Kraenzlin ME, Bloom SR 1983 New Somatostatin Analogue for home treatment of endocrine tumours. Gut 24: A984.CrossRefGoogle Scholar
  29. 29.
    Kraenzlin ME, Ch’ng JLC, Wood SM, Bloom SR 1984 Remission of symptoms and shrinkage of metastasis with long term treatment with somatostatin analogue. Gut 25: A576.Google Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Peter Marbach
    • 1
  • Michael Neufeld
    • 1
  • Janos Pless
    • 1
  1. 1.Preclinical and Clinical Research Dept.Sandoz Ltd.BaselSwitzerland

Personalised recommendations